Drug intelligence / Profile preview

ibuprofen + acetaminophen (Laboratorios Silanes)

Development stage
Phase 4
Lead developer
Laboratorios Silanes
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a fixed-dose combination (FDC) of ibuprofen and acetaminophen developed by Laboratorios Silanes S.A. de C.V. for the management of pain and fever. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the synthesis of pro-inflammatory prostaglandins. Acetaminophen (paracetamol) is an analgesic and antipyretic agent that primarily acts through central nervous system mechanisms, including the inhibition of central prostaglandin synthesis and potentially the modulation of the endocannabinoid system. The combination is designed to provide enhanced analgesic efficacy by utilizing two distinct mechanisms of action. Laboratorios Silanes has developed this FDC in both a pediatric oral suspension (100 mg ibuprofen and 125 mg acetaminophen per 5 mL) and a tablet formulation (200 mg ibuprofen and 500 mg acetaminophen).

Brand names
Multiprofen
Other names
Ibuprofen/Acetaminophen Fixed dose combinationIbuprofen/Acetaminophen oral suspensionIbuprofen/Acetaminophen tablets
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on ibuprofen + acetaminophen (Laboratorios Silanes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + acetaminophen (Laboratorios Silanes).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call